<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39322246</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1755-5248</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Drug and therapeutics bulletin</Title><ISOAbbreviation>Drug Ther Bull</ISOAbbreviation></Journal><ArticleTitle>Intravenous vitamin C for COVID-19: no benefit.</ArticleTitle><Pagination><StartPage>148</StartPage><MedlinePgn>148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/dtb.2024.000055</ELocationID><Abstract><AbstractText><b>Overview of:</b> LOVIT-COVID Investigators. Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials. <i>JAMA</i> 2023;330:1745-59.</AbstractText><CopyrightInformation>Â© BMJ Publishing Group Limited 2024. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Ther Bull</MedlineTA><NlmUniqueID>0112037</NlmUniqueID><ISSNLinking>0012-6543</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PQ6CK8PD0R</RegistryNumber><NameOfSubstance UI="D001205">Ascorbic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014815">Vitamins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001205" MajorTopicYN="Y">Ascorbic Acid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="Y">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014815" MajorTopicYN="N">Vitamins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</Keyword><Keyword MajorTopicYN="N">Health Care Quality, Access, and Evaluation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>20</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39322246</ArticleId><ArticleId IdType="doi">10.1136/dtb.2024.000055</ArticleId><ArticleId IdType="pii">dtb.2024.000055</ArticleId></ArticleIdList></PubmedData></PubmedArticle>